keyword
https://read.qxmd.com/read/37253609/nocturnal-high-flow-nasal-cannula-therapy-and-sinonasal-symptoms-during-cystic-fibrosis-exacerbations
#21
JOURNAL ARTICLE
Michael D Davis, Justin Brockbank, Ryan Hayden, Michael S Schechter, Bruce K Rubin
BACKGROUND: Both nasal obstruction and sleep disturbance are common in patients with cystic fibrosis (CF). In patients with obstructive sleep apnea (OSA), studies suggest that these conditions are related and that nasal congestion improves with CPAP therapy. We hypothesized that subjects admitted to hospital for therapy of an exacerbation of CF would have both nasal symptoms and sleep disturbance and that these would improve with the initiation of nocturnal high-flow nasal cannula therapy (HFNC)...
November 2023: Respiratory Care
https://read.qxmd.com/read/37228264/ers-international-congress-2022-highlights-from-the-paediatrics-assembly
#22
REVIEW
Cristina Ardura-Garcia, Katharina Kainz, Maria Christina Mallet, Laura Petrarca, Jasna Rodman Berlot, Monique Slaats, Carmen Streibel, Susanne Vijverberg, Emma E Williams, Myrofora Goutaki, Diane M Gray, Anna Lavizzari, Rory E Morty, Marijke Proesmans, Dirk Schramm, Mirjam Stahl, Angela Zacharasiewicz, Alexander Moeller, Mariëlle W Pijnenburg
This review has been prepared by the Early Career Members and Chairs of the European Respiratory Society (ERS) Assembly 7: Paediatrics. We here summarise the highlights of the advances in paediatric respiratory research presented at the ERS International Congress 2022. The eight scientific groups of this Assembly cover a wide range of research areas, including respiratory physiology and sleep, asthma and allergy, cystic fibrosis (CF), respiratory infection and immunology, neonatology and intensive care, respiratory epidemiology, bronchology, and lung and airway developmental biology...
May 2023: ERJ Open Research
https://read.qxmd.com/read/37210228/characterization-of-sleep-in-emerging-adults-with-cystic-fibrosis-on-elexacaftor-tezacaftor-ivacaftor
#23
JOURNAL ARTICLE
Lisa J Meltzer, Jane E Gross
No abstract text is available yet for this article.
May 18, 2023: Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society
https://read.qxmd.com/read/37180712/individualized-approach-to-elexacaftor-tezacaftor-ivacaftor-dosing-in-cystic-fibrosis-in-response-to-self-reported-anxiety-and-neurocognitive-adverse-events-a-case-series
#24
JOURNAL ARTICLE
Hisham Ibrahim, Hammad Danish, David Morrissey, Kevin F Deasy, Mairead McCarthy, James Dorgan, Claire Fleming, Ciara Howlett, Sarah Twohig, Tamara Vagg, Desmond M Murphy, Michael Maher, Barry J Plant
The prevalence of mental health disorders is high among people with Cystic Fibrosis. The psychological symptoms in CF are associated with poor adherence, worse treatment outcomes, and greater health utilization/cost. Mental health and neurocognitive Adverse Events (AEs) have been reported with all available Cystic Fibrosis Transmembrane conductance Regulator (CFTR) modulators in small groups of patients. We report our experience with a dose reduction strategy in 10 of our patients on elexacaftor/tezacaftor/ivacaftor (7...
2023: Frontiers in Pharmacology
https://read.qxmd.com/read/37159780/a-systematic-review-of-cystic-fibrosis-in-children-can-non-medical-therapy-options-lead-to-a-better-mental-health-outcome
#25
REVIEW
Natalie A Gonzalez, Sana M Dayo, Umaima Fatima, Aaiyat Sheikh, Chaitanya S Puvvada, Faiza H Soomro, Hafsa A Osman, Merna Haridi, Safeera Khan
Cystic fibrosis (CF) is a chronic disorder that begins at an early age, so it is crucial to be aware of the physical and emotional burden placed on individuals suffering from it and their families. It significantly impacts an individual's life; therefore, it is essential to acknowledge the effects of the disease on physical and mental health. Our systematic review aims to highlight the areas of life affected by cystic fibrosis and evaluate various non-medical treatment options that may support the mental health of CF patients...
April 2023: Curēus
https://read.qxmd.com/read/37099091/self-reported-quantity-and-quality-of-sleep-in-children-and-adolescents-with-a-chronic-condition-compared-to-healthy-controls
#26
JOURNAL ARTICLE
Camille F M Biemans, Sanne L Nijhof, Jan Willem Gorter, Gonneke J W M Stevens, Elise van de Putte, Johanna W Hoefnagels, Anemone van den Berg, Cornelis K van der Ent, Jeroen Dudink, Olaf W Verschuren
To assess self-reported quantity and quality of sleep in Dutch children with a chronic condition compared to healthy controls and to the recommended hours of sleep for youth. Sleep quantity and quality were analyzed in children with a chronic condition (cystic fibrosis, chronic kidney disease, congenital heart disease, (auto-)immune disease, and medically unexplained symptoms (MUS); n = 291; 15 ± 3.1 years, 63% female. A subset of 171 children with a chronic condition were matched to healthy controls using Propensity Score matching, based on age and sex, ratio 1:4...
April 26, 2023: European Journal of Pediatrics
https://read.qxmd.com/read/36982578/sleep-disordered-breathing-and-chronic-respiratory-infections-a-narrative-review-in-adult-and-pediatric-population
#27
REVIEW
Paola Faverio, Umberto Zanini, Anna Monzani, Gianfranco Parati, Fabrizio Luppi, Carolina Lombardi, Elisa Perger
Sleep-disordered breathing (SDB) comprises different diseases characterized by abnormal respiratory patterns during sleep including obstructive sleep apnea. SDB prevalence and impact in patients with chronic respiratory infections have been only marginally studied. The purpose of this narrative review is to report the prevalence and impact of SDB in chronic respiratory infections, including cystic fibrosis (CF), bronchiectasis and mycobacterial infections, and explore the possible pathophysiological mechanisms...
March 13, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/36833376/effects-of-elexacaftor-tezacaftor-ivacaftor-on-cardiorespiratory-polygraphy-parameters-and-respiratory-muscle-strength-in-cystic-fibrosis-patients-with-severe-lung-disease
#28
JOURNAL ARTICLE
Alessandro Giallongo, Giuseppe Fabio Parisi, Maria Papale, Sara Manti, Enza Mulé, Donatella Aloisio, Vito Terlizzi, Novella Rotolo, Salvatore Leonardi
BACKGROUND: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators represent targeted therapies directly acting on the CFTR channel. The triple therapy Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) has been demonstrated to improve lung function and quality of life in cystic fibrosis (CF) patients. However, the effects of ELX/TEZ/IVA on sleep-disordered breathing (SDB) and respiratory muscle strength are poorly studied. The aim of this study was to assess the effects of ELX/TEZ/IVA in patients with CF and severe lung disease on cardiorespiratory polygraphy parameters, maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) measures...
February 9, 2023: Genes
https://read.qxmd.com/read/36756720/risk-of-new-onset-and-prevalent-disease-in-chronic-rhinosinusitis-a-prospective-cohort-study
#29
JOURNAL ARTICLE
Annemarie G Hirsch, Brian S Schwartz, Cara Nordberg, Bruce K Tan, Robert P Schleimer, Robert C Kern, Anju T Peters, Karen Bandeen-Roche, Ashton E Lehmann
BACKGROUND: Chronic rhinosinusitis (CRS) is accompanied by burdensome co-morbid conditions. Understanding the relative timing of these conditions' onset could inform disease prevention, detection, and management. OBJECTIVE: To evaluate the association between CRS and new onset and prevalent asthma, non-cystic fibrosis bronchiectasis (NCFBE), chronic obstructive pulmonary disease (COPD), gastroesophageal reflux disease (GERD), and obstructive sleep apnea (OSA). METHODS: We conducted a prospective cohort study among primary care patients using a detailed medical and symptom questionnaire in 2014 and again in 2020...
February 9, 2023: International Forum of Allergy & Rhinology
https://read.qxmd.com/read/36738326/effects-of-cftr-modulator-triple-therapy-on-sinunasal-symptoms-in-children-and-adults-with-cystic-fibrosis
#30
JOURNAL ARTICLE
Sebastian F N Bode, Hannes Rapp, Nadine Lienert, Heike Appel, Dorit Fabricius
PURPOSE: Sinunasal symptoms and chronic rhinusinutitis are common in patients with cystic fibrosis. Cystic fibrosis transmembrane regulator (CFTR) modulators have led to dramatic improvements of respiratory symptoms and quality of life in patients with cystic fibrosis. This study aims to evaluate subjective and objective sinunasal symptoms after start of CFTR-modulator triple therapy. METHODS: 43 patients (n = 6 < 18 years), treated with highly effective CFTR-modulator therapy with elexacaftor-tezacaftor-ivacaftor (ELX/TEZ/IVA) were included, as were 20 controls with cystic fibrosis but without CFTR-modulator therapy (n = 6 < 18 years)...
February 4, 2023: European Archives of Oto-rhino-laryngology
https://read.qxmd.com/read/36562554/impact-of-elexacaftor-tezacaftor-ivacaftor-on-depression-and-anxiety-in-cystic-fibrosis
#31
JOURNAL ARTICLE
Lijia Zhang, Dana Albon, Marieke Jones, Heather Bruschwein
BACKGROUND: Cystic fibrosis (CF) is associated with worsening of depression and anxiety symptoms. Elexacaftor/tezacaftor/ivacaftor (Trikafta®), a cystic fibrosis transmembrane regulator (CFTR) modulator approved in 2019, significantly improves lung function, decreases pulmonary exacerbations, and improves quality of life. Studies are needed to evaluate the effects of Trikafta on symptoms of anxiety and depression. RESEARCH QUESTION: Do adults with CF report a change in depression and anxiety symptoms after Trikafta initiation? STUDY DESIGN AND METHODS: A retrospective chart review was conducted of patients with CF ( n  = 127) receiving care from January 2015 through February 2022...
2022: Therapeutic Advances in Respiratory Disease
https://read.qxmd.com/read/36507150/editorial-insights-in-pediatric-pulmonology-2021
#32
EDITORIAL
Federica Porcaro, Renato Cutrera
No abstract text is available yet for this article.
2022: Frontiers in Pediatrics
https://read.qxmd.com/read/36437445/obstructive-sleep-apnea-and-nocturnal-hypoxemia-in-adult-patients-with-cystic-fibrosis
#33
JOURNAL ARTICLE
Matthias Welsner, Sarah Dietz-Terjung, Florian Stehling, Tim Schulte, Ute Niehammer, Fatma-Ezzahra Gahbiche, Christian Taube, Svenja Strassburg, Christoph Schoebel, Gerhard Weinreich, Sivagurunathan Sutharsan
BACKGROUND: Obstructive sleep apnea (OSA), nocturnal hypoxemia and excessive daytime sleepiness (EDS) are common comorbidities in people with cystic fibrosis (pwCF). Most of the data showing this originates from children and adolescents. The aim of this study was to collect data on sleep parameters, EDS and pulmonary function from a large cohort of adult pwCF. METHODS: Full overnight polysomnography (PSG) was performed. EDS was determined using the Epworth Sleepiness Scale (ESS)...
November 28, 2022: BMC Pulmonary Medicine
https://read.qxmd.com/read/36402730/steps-ahead-optimising-physical-activity-in-adults-with-cystic-fibrosis-a-pilot-randomised-trial-using-wearable-technology-goal-setting-and-text-message-feedback
#34
JOURNAL ARTICLE
Máire Curran, Audrey C Tierney, Louise Collins, Lauren Kennedy, Ciara McDonnell, Andrew J Jurascheck, Ali Sheikhi, Cathal Walsh, Brenda Button, Brian Casserly, Roisin Cahalan
BACKGROUND: Regular participation in physical activity (PA) is encouraged for people with Cystic Fibrosis (CF). This study aimed to assess the effectiveness of an intervention using wearable technology, goal setting and text message feedback on PA and health outcomes in people with CF. METHODS: This was a pilot randomised trial conducted at University Hospital Limerick. Participants were randomly assigned to the intervention (INT) or active comparator (AC). The 12-week intervention consisted of wearable technology (Fitbit Charge 2) which was remotely monitored, and participants set step count goals...
November 16, 2022: Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society
https://read.qxmd.com/read/36344081/management-of-mental-health-in-cystic-fibrosis
#35
REVIEW
Christina Jayne Bathgate, Michelle Hjelm, Stephanie S Filigno, Beth A Smith, Anna M Georgiopoulos
This article is intended for use among all cystic fibrosis care team members. It covers common mental health concerns and their unique presentations in persons with cystic fibrosis (pwCF) in areas such as depression, anxiety, trauma, behavioral disorders emerging in childhood, sleep, problematic eating patterns, and the impact of substance use. Furthermore, the authors address ways to manage these mental health symptoms through risk assessment, psychological interventions, and/or psychotropic medications. Quick reference tables are provided for evidence-based psychological interventions and medications often used for mental health conditions in pwCF...
December 2022: Clinics in Chest Medicine
https://read.qxmd.com/read/36244873/pulmonary-disorders-in-pregnancy-bronchiectasis-cystic-fibrosis-sarcoidosis-and-interstitial-diseases
#36
REVIEW
Alena J Haines, Peter G Middleton
This chapter aims to provide expert guidance to obstetricians, general practitioners, allied health staff and women with lung disease about the interactions between pregnancy and different lung diseases. This chapter will cover other airway diseases such as bronchiectasis and cystic fibrosis (CF) together with sarcoidosis and interstitial lung disease (ILD), noting that another chapter covers asthma. The physiological changes which occur in pregnancy, such as the changes in airway physiology, resting ventilation and sleep, are summarised in another chapter...
December 2022: Best Practice & Research. Clinical Obstetrics & Gynaecology
https://read.qxmd.com/read/36183784/sex-and-gender-in-lung-diseases-and-sleep-disorders-a-state-of-the-art-review-part-2
#37
REVIEW
Amik Sodhi, Katherine Cox-Flaherty, Meredith Kendall Greer, Tasnim I Lat, Yuqing Gao, Deepika Polineni, Margaret A Pisani, Ghada Bourjeily, Marilyn K Glassberg, Carolyn D'Ambrosio
There is now ample evidence that differences in sex and gender contribute to the incidence, susceptibility, presentation, diagnosis, and clinical course of many lung diseases. Some conditions are more prevalent in women, such as pulmonary arterial hypertension and sarcoidosis. Some life stages-such as pregnancy-are unique to women and can affect the onset and course of lung disease. Clinical presentation may differ as well, such as the higher number of exacerbations experienced by women with cystic fibrosis (CF), more fatigue in women with sarcoidosis, and more difficulty in achieving smoking cessation...
February 2023: Chest
https://read.qxmd.com/read/36062879/the-circadian-system-in-cystic-fibrosis-mice-is-regulated-by-histone-deacetylase-6
#38
JOURNAL ARTICLE
Eric Barbato, Rebecca Darrah, Thomas J Kelley
Disordered sleep experienced by people with cystic fibrosis (CF) suggest a possible disruption in circadian regulation being associated with the loss of cystic fibrosis transmembrane conductance regulator (Cftr) function. To test this hypothesis, circadian regulation was assessed in a F508del/F508del CF mouse model. CF mice exhibited significant alterations in both timing of locomotor activity and in mean activity per hour in both light-dark (LD) and dark-dark (DD) photoperiods compared to wild type (WT) controls...
September 5, 2022: American Journal of Physiology. Cell Physiology
https://read.qxmd.com/read/36018862/determinants-of-coronavirus-disease-2019-infection-by-artificial-intelligence-technology-a-study-of-28-countries
#39
JOURNAL ARTICLE
Hsiao-Ya Peng, Yen-Kuang Lin, Phung-Anh Nguyen, Jason C Hsu, Chun-Liang Chou, Chih-Cheng Chang, Chia-Chi Lin, Carlos Lam, Chang-I Chen, Kai-Hsun Wang, Christine Y Lu
OBJECTIVES: The coronavirus disease 2019 pandemic has affected countries around the world since 2020, and an increasing number of people are being infected. The purpose of this research was to use big data and artificial intelligence technology to find key factors associated with the coronavirus disease 2019 infection. The results can be used as a reference for disease prevention in practice. METHODS: This study obtained data from the "Imperial College London YouGov Covid-19 Behaviour Tracker Open Data Hub", covering a total of 291,780 questionnaire results from 28 countries (April 1~August 31, 2020)...
2022: PloS One
https://read.qxmd.com/read/35871972/acceptability-and-feasibility-of-a-brief-behavioral-sleep-intervention-for-youth-with-cf
#40
JOURNAL ARTICLE
Kimberly S Canter, Abigail Strang, Sophie Wilks, Katherine Okonak, Aaron Chidekel
Youth with CF are at increased risk for physiological and behavioral sleep difficulties due to disease-specific symptoms and more general pediatric sleep challenges. Despite evidence suggesting that behavioral sleep interventions are effective for improving common sleep difficulties, no interventions exist for youth with CF. SLEEP-CF was designed to fill this gap by providing tailored, flexible behavioral sleep support to youth with CF. Results suggest that SLEEP-CF is an acceptable and feasible behavioral sleep intervention, even in a population with normative sleep habits...
July 21, 2022: Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society
keyword
keyword
12855
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.